Vaxart, Inc. announced that W. Mark Watson was appointed to the Company's Board of Directors, effective August 4, 2022. Mr. Watson will become Chair of the Company's Audit Committee, effective October 1. Robert A. Ye did, a member of the Board and the Audit Committee, was appointed Interim Chairperson of the Audit Committee, to serve until Mr. Watson becomes Chair. The Company also announced that after years of service and dedication, Karen Wilson stepped down from the Board of Directors, effective August 4, 2022.Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu and its predecessor, most recently as Central Florida Marketplace Leader.

He has served as lead audit partner and lead client service partner on public companies ranging from middle market firms to Fortune 500 enterprises. Mr. Watson also serves as Chairman of the Board of Directors and Chairman of the Audit Committee of Inhibitor Therapeutics, Inc. He previously served as a director and member of the Audit Committee of Sykes Enterprises, Inc. and BioDelivery Sciences International, Inc. A member of American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants, Mr. Watson is qualified to serve on the Board due to his expertise in public accounting and his experience with life science and pharmaceutical companies. He received his undergraduate degree in Accounting from Marquette University.